Ipilimumab: Perbedaan antara revisi
Konten dihapus Konten ditambahkan
k Bot: Menambahkan tag <references /> yang hilang |
Rescuing 1 sources and tagging 0 as dead.) #IABot (v2.0.8.2 |
||
Baris 29:
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D04603
| synonyms = BMS-734016,<ref>{{cite web|title=Yervoy, ipilimumab (BMS-734016) - Product Profile - BioCentury|url=http://www.biocentury.com/products/bms-734016|website=BioCentury Online Intelligence|publisher=BioCentury Publications|accessdate=11 August 2016|archive-date=2016-08-12|archive-url=https://web.archive.org/web/20160812100312/http://www.biocentury.com/products/bms-734016|dead-url=yes}}</ref> MDX-010,<ref>{{cite press release | url = http://www.ama-assn.org/resources/doc/usan/ipilimumab2.doc | title = STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL - ipilimumab | author = USAN | publisher = [[American Medical Association]] (AMA) | accessdate = 2013-01-12 }}</ref> MDX-101
<!-- Chemical data -->
| C=6742 | H=9972 | N=1732 | O=2004 | S=40
| |||